{"id":18256,"date":"2022-08-01T17:07:38","date_gmt":"2022-08-01T11:37:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18256"},"modified":"2022-11-24T18:35:25","modified_gmt":"2022-11-24T13:05:25","slug":"generalized-myasthenia-gravis-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market","title":{"rendered":"Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis (gMG) Treatment Market?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a043b53a6068\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a043b53a6068\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\/#Changing_Dynamics_of_Generalized_Myasthenia_Gravis_Market_Landscape\" >Changing Dynamics of Generalized Myasthenia Gravis Market Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\/#FcRn_Antagonists_may_lead_the_Generalized_Myasthenia_Gravis_Market\" >FcRn Antagonists may lead the Generalized Myasthenia Gravis Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\/#Generalized_Myasthenia_Gravis_Treatment_Market_is_all_Set_to_Grow_Significantly\" >Generalized Myasthenia Gravis Treatment Market is all Set to Grow Significantly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Though a rare disease, generalized myasthenia gravis (gMG) still affects around <strong>60,000<\/strong> people in the US and another <strong>100,000<\/strong> in EU-5 and Japan. <\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>As per our analysis, the<a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-epidemiology-forecast\"> total diagnosed prevalent cases of gMG<\/a> were approx 116K in the 7MM in 2021. These numbers are further estimated to increase by 2032. Moreover, the number of females affected was twice as compared to males in the US in 2021, and it is estimated that the gMG prevalence will increase in the US by 2032.&nbsp;<\/strong><\/p><\/blockquote>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-974e48d2-1391-4e4f-b4f2-22670d8d803f\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.2.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-f3ktjcs-478-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-f3ktjcs-481-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-f3ktjcs-482-\"><rect fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 283.5 92 L 283.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 92 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 67.5 92 L 67.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 318.5 L 499 318.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 273.5 L 499 273.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 228.5 L 499 228.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 182.5 L 499 182.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 137.5 L 499 137.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 91.5 L 499 91.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"271\" width=\"431\" x=\"68\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.44443416595459 227.5)\" x=\"26.44443416595459\" y=\"227.5\">Total prevalent cases (in thousands)<\/text><path class=\"highcharts-axis-line\" d=\"M 68 92 L 68 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-f3ktjcs-481-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><rect aria-label=\"Males, 13.5. Total prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"122\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"104\" x=\"55.5\" y=\"149.5\"><\/rect><rect aria-label=\"Females, 26.5. Total prevalent cases (in thousands).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"239\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"104\" x=\"271.5\" y=\"32.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Generalized Myasthenia Gravis Epidemiological<tspan dy=\"21\" x=\"255\">\u200b<\/tspan>Insights (in 2021)<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"73\">Gender-specific Cases<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(68,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(90,126)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">13.5<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>13.5<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(306,9)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">26.5<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>26.5<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"175.75\" y=\"382\">Males<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"391.25\" y=\"382\">Females<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"322\">5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"277\">10<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"232\">15<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"186\">20<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"141\">25<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"96\">30<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Generalized Myasthenia Gravis Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Generalized Myasthenia Gravis Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-f3ktjcs-482-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Generalized Myasthenia Gravis Epidemiological Insights (in 2021)\"},\"subtitle\":{\"text\":\"Gender-specific Cases\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Total prevalent cases (in thousands)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Total prevalent cases (in thousands)\\\"\\n\\\"Males \\\";13.5\\n\\\"Females\\\";26.5\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Total prevalent cases (in thousands)\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Generalized Myasthenia Gravis Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-974e48d2-1391-4e4f-b4f2-22670d8d803f\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>In myasthenia gravis (MG), the immune system produces AChR antibodies that interfere with communication between nerves and muscles, resulting in weakness. Generalized myasthenia gravis diagnosis is measured by serum acetylcholine receptor (AChR) antibody levels, electromyography, and bedside tests (ice pack test, rest test).<\/p>\n\n\n\n<p>Consensus clinical practice guidelines recommend <strong>thymectomy (the surgical removal of the thymus gland)<\/strong> as an effective generalized <a href=\"https:\/\/www.delveinsight.com\/blog\/myasthenia-gravis-market\">myasthenia gravis treatment<\/a> for all patients with thymoma and patients aged 10\u201355 years without thymoma. Most patients with myasthenia gravis develop antibodies to acetylcholine receptors (AChRs); these antibodies bind to AChRs on the postsynaptic membrane at the neuromuscular junction and interrupt the neuromuscular transmission. About <strong>80%<\/strong> of patients with gMG have AChR antibodies and are treated by acetylcholine esterase inhibitors. <strong>Pyridostigmine<\/strong> is a cholinesterase inhibitor that is a first-line, symptomatic generalized myasthenia gravis treatment. Other major generalized myasthenia gravis treatments include other <strong>AChE inhibitors, corticosteroids, non-steroidal immunosuppressants<\/strong> like azathioprine, plasma exchange, and IV immune globulin. <strong>Eculizumab (Soliris\u00ae)<\/strong> was the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-pipeline-insight\">targeted generalized myasthenia gravis treatment<\/a> approved for treating anti-antibody-positive AChR-Ab+ gMG patients. It is a first-in-class complement inhibitor (C5) approved in 2017 in the US. SOLIRIS is administered by intravenous infusion every 2 weeks.<\/p>\n\n\n\n<p>Being the first-to-market drug, <strong>SOLIRIS <\/strong>pocketed huge sales due to its monopoly and an exorbitant annual cost of therapy of <strong>~USD 470,000<\/strong> per patient. Moreover, challenges like treatment--associated side-effects, inconsistent efficacy to control exacerbations, and high cost meant a high unmet need for safe, efficacious, and cost-effective <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-pipeline-insight\">generalized myasthenia gravis therapies<\/a> still exists. To cater to this need, companies around the globe are working to bring innovative generalized myasthenia gravis therapies in the gMG market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Changing_Dynamics_of_Generalized_Myasthenia_Gravis_Market_Landscape\"><\/span><strong>Changing Dynamics of Generalized Myasthenia Gravis Market Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After a long time, the second molecule to enter the generalized myasthenia gravis market was <strong>VYVGART (Efgartigimod alfa-fcab). <\/strong>It is the first FcRn antagonist to enter generalized myasthenia gravis treatment market, with a novel MoA and significant efficacy. It is indicated for the treatment of adults with AChR-AB+ gMG in the US and in Japan for the <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/generalized-myasthenia-gravis\">treatment of adults with gMG<\/a> who do not have sufficient response to the standard of care steroids or non-steroidal immunosuppressive therapies (ISTs).<\/p>\n\n\n\n<p>This was followed by <strong>ULTOMIRIS (Ravulizumab)<\/strong> by <strong>Alexion Pharmaceuticals<\/strong>. It is the first and only long-acting C5 complement inhibitor, offering immediate, complete, and sustained complement inhibition. It is administered intravenously every 8 weeks in adult patients, following a loading dose. Ravulizumab received US FDA approval in April 2022 under priority review.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155536\/Key-Companies-in-the-gMG-Market.png\" alt=\"gMG Companies\" class=\"wp-image-18258\" width=\"717\" height=\"273\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155536\/Key-Companies-in-the-gMG-Market.png 717w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155536\/Key-Companies-in-the-gMG-Market-300x114.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155536\/Key-Companies-in-the-gMG-Market-150x57.png 150w\" sizes=\"(max-width: 717px) 100vw, 717px\" \/><figcaption><strong>Leading Players in the gMG Therapeutics Segment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Furthermore, the other leading companies such as <strong>UCB Biopharma, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research &amp; Development, LLC, Immunovant Sciences GmbH<\/strong>, and others are also actively working in the generalized myasthenia gravis market to improve the treatment outlook.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FcRn_Antagonists_may_lead_the_Generalized_Myasthenia_Gravis_Market\"><\/span><strong>FcRn Antagonists may lead the Generalized Myasthenia Gravis Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There is a list of late-stage assets with distinct MoA being developed for treating gMG patients and are expected to enter the United States, EU5 (Germany, Italy, France, Spain, the United Kingdom), and the Japanese generalized myasthenia gravis market in the next few years. Few of the FcRn molecules in development include <strong>Rozanolixizumab (UCB Biopharma), SC efgartigimod (Argenx-Halozyme), Nipocalimab (Janssen), <\/strong>and <strong>Batoclimab (Immunovant Sciences).<\/strong> The detailed pipeline analysis of the upcoming molecules is mentioned below:<\/p>\n\n\n\n<div class=\"visualizer-front-container visualizer-lazy-render\" id=\"chart_wrapper_visualizer-18268-1144189023\"><style type=\"text\/css\" name=\"visualizer-custom-css\" id=\"customcss-visualizer-18268\">.locker,.locker-loader{position:absolute;top:0;left:0;width:100%;height:100%}.locker{z-index:1000;opacity:.8;background-color:#fff;-ms-filter:\"progid:DXImageTransform.Microsoft.Alpha(Opacity=80)\";filter:alpha(opacity=80)}.locker-loader{z-index:1001;background:url(https:\/\/www.delveinsight.com\/blog\/wp-content\/plugins\/visualizer\/images\/ajax-loader.gif) no-repeat center center}.dt-button{display:none!important}.visualizer-front-container.visualizer-lazy-render{content-visibility: auto;}.google-visualization-controls-categoryfilter label.google-visualization-controls-label {vertical-align: middle;}.google-visualization-controls-categoryfilter li.goog-inline-block {margin: 0 0.2em;}.google-visualization-controls-categoryfilter li {padding: 0 0.2em;}.visualizer-front-container .dataTables_scrollHeadInner{margin: 0 auto;}<\/style><div id=\"visualizer-18268-1144189023\" class=\"visualizer-front  visualizer-front-18268\"><\/div><!-- Not showing structured data for chart 18268 because title is empty --><\/div>\n\n\n\n<p><strong>VYVGART (efgartigimod)<\/strong> by <strong>Argenx <\/strong>was launched in January 2022 and has pocketed sales beyond estimates in its first quarter (1Q22). Argenx is also developing SC efgartigimod in collaboration with subcutaneous delivery systems\u2019 player, Halozyme, to treat gMG patients. The company announced a positive data readout of its Phase III studies in 2H22. It also announced plans to file BLA by the end of 2022. Argenx also plans to commercialize the asset with a different brand name, as it plans to take a second bite at the <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-market\">generalized myasthenia gravis treatment market<\/a>. The asset is anticipated to achieve high generalized myasthenia gravis market penetration owing to its long-acting nature and favorable ease of administration. It is expected to enter the US generalized myasthenia gravis treatment market by 2023.<\/p>\n\n\n\n<p>On the other side, <strong>UCB Pharma<\/strong> is all-set to compete in the generalized myasthenia gravis market with its FcRn antagonist in subcutaneous formulation, <strong>rozanolixizumab<\/strong>. The company announced positive topline results from the <strong>Phase III MycarinG study<\/strong> in December 2021. One major advantage of rozanolixizumab is that it is being investigated in overall gMG Class II\u2013IV patients with either AChR or MuSK antibodies.<\/p>\n\n\n\n<p>Another promising FcRn antagonist set to compete in gMG space is <strong>nipocalimab<\/strong>. Being developed by <strong>Momenta Pharmaceuticals<\/strong> (acquired by J&amp;J in 2020 for USD 6.5 billion), nipocalimab may represent a \u2018pipeline-in-a-drug\u2019 as it is being investigated in around 10 rare indications, including MG. The drug\u2019s mechanism to take advantage of the body\u2019s natural mechanism for recycling and removing antibodies from the bloodstream fits the purpose of reducing the amount of IgG in the patient's bloodstream.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Generalized_Myasthenia_Gravis_Treatment_Market_is_all_Set_to_Grow_Significantly\"><\/span><strong>Generalized Myasthenia Gravis Treatment Market is all Set to Grow Significantly<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-market\">generalized myasthenia gravis market<\/a> currently accounts for more than USD 2,600 million, as per DelveInsight\u2019s analysis.<\/strong><\/p><\/blockquote>\n\n\n\n<p>New generalized myasthenia gravis treatments, such as FcRn antagonists and B-cell targeted therapies, provide novel generalized myasthenia gravis treatment options for the gMG patients\u2019 refractory to steroids\/immunosuppressants. New generalized myasthenia gravis drugs that focus on formulations for ease of administration improve compliance among chronic patients and patients looking for drugs that provide safe and stable responses. This is likely to drive generalized myasthenia gravis treatment market growth in the future. Last but not least, there is an increasing effort by regulatory agencies and patient organizations like Myasthenia Gravis Foundation to create awareness about myasthenia gravis, thus contributing to earlier diagnosis.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/generalized-myasthenia-gravis\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-1024x256.png\" alt=\"gMG Market outlook\" class=\"wp-image-18259\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155630\/Generalized-Myasthenia-Gravis-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1659349155413\"><strong class=\"schema-faq-question\"><strong>1. What is Generalized Myasthenia Gravis?<\/strong><\/strong> <p class=\"schema-faq-answer\">gMG is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles (voluntary) that worsens after periods of activity and improves after periods of rest. It affects muscles, especially those responsible for controlling the eyes, face, mouth, throat, and limbs.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1659349167536\"><strong class=\"schema-faq-question\"><strong>2. What are the generalized myasthenia gravis symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Myasthenia gravis causes muscle weakness that develops as the affected muscle is engaged. Muscle weakness might come and go because symptoms normally improve with rest. However, the generalized myasthenia gravis symptoms normally worsen with time, reaching their peak within a few years of the disease's inception. The common generalized myasthenia gravis symptoms include weakness of the eye muscle, blurred or double vision, difficult swallowing, shortness of breath, and others.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1659349185090\"><strong class=\"schema-faq-question\"><strong>3. How generalized myasthenia gravis is diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Generalized myasthenia gravis diagnosis is measured by serum acetylcholine receptor (AChR) antibody levels, electromyography, and bedside tests (ice pack test, rest test).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1659349203089\"><strong class=\"schema-faq-question\"><strong>4. Which companies are working in the generalized myasthenia gravis market?<\/strong><\/strong> <p class=\"schema-faq-answer\">The leading companies such as Alexion Pharmaceuticals, Argenx, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research &amp; Development, LLC, Immunovant Sciences GmbH, and others are actively working in the generalized myasthenia treatment market.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1659349215761\"><strong class=\"schema-faq-question\"><strong>5. Which are the few \u00a0FcRn molecules in gMG pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">Few of the FcRn molecules in development include Rozanolixizumab (UCB Biopharma), SC efgartigimod (Argenx-Halozyme), Nipocalimab (Janssen), and Batoclimab (Immunovant Sciences).<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 people in the US and another 100,000 in EU-5 and Japan. As per our analysis, the total diagnosed prevalent cases of gMG were approx 116K in the 7MM in 2021. These numbers are further estimated to increase by 2032. Moreover, the number of [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":18257,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18983,19602,19601,19600,19603,18979],"industry":[17225],"therapeutic_areas":[17227,17234],"class_list":["post-18256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-generalized-myasthenia-gravis","tag-generalized-myasthenia-gravis-market","tag-generalized-myasthenia-gravis-treatment","tag-gmg","tag-gmg-market","tag-gmg-treatment","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging FcRn Antagonists for Generalized Myasthenia Gravis Treatment<\/title>\n<meta name=\"description\" content=\"Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment expected to enter therapeutics market\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging FcRn Antagonists for Generalized Myasthenia Gravis Treatment\" \/>\n<meta property=\"og:description\" content=\"Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment expected to enter therapeutics market\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-01T11:37:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-24T13:05:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging FcRn Antagonists for Generalized Myasthenia Gravis Treatment","description":"Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment expected to enter therapeutics market","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Emerging FcRn Antagonists for Generalized Myasthenia Gravis Treatment","og_description":"Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment expected to enter therapeutics market","og_url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-08-01T11:37:38+00:00","article_modified_time":"2022-11-24T13:05:25+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market","name":"Emerging FcRn Antagonists for Generalized Myasthenia Gravis Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market.png","datePublished":"2022-08-01T11:37:38+00:00","dateModified":"2022-11-24T13:05:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment expected to enter therapeutics market","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349155413"},{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349167536"},{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349185090"},{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349203089"},{"@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349215761"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market.png","width":772,"height":482,"caption":"generalized-myasthenia-gravis-treatment-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349155413","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349155413","name":"1. What is Generalized Myasthenia Gravis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"gMG is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles (voluntary) that worsens after periods of activity and improves after periods of rest. It affects muscles, especially those responsible for controlling the eyes, face, mouth, throat, and limbs.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349167536","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349167536","name":"2. What are the generalized myasthenia gravis symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Myasthenia gravis causes muscle weakness that develops as the affected muscle is engaged. Muscle weakness might come and go because symptoms normally improve with rest. However, the generalized myasthenia gravis symptoms normally worsen with time, reaching their peak within a few years of the disease's inception. The common generalized myasthenia gravis symptoms include weakness of the eye muscle, blurred or double vision, difficult swallowing, shortness of breath, and others.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349185090","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349185090","name":"3. How generalized myasthenia gravis is diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Generalized myasthenia gravis diagnosis is measured by serum acetylcholine receptor (AChR) antibody levels, electromyography, and bedside tests (ice pack test, rest test).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349203089","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349203089","name":"4. Which companies are working in the generalized myasthenia gravis market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The leading companies such as Alexion Pharmaceuticals, Argenx, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research &amp; Development, LLC, Immunovant Sciences GmbH, and others are actively working in the generalized myasthenia treatment market.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349215761","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/generalized-myasthenia-gravis-treatment-market#faq-question-1659349215761","name":"5. Which are the few \u00a0FcRn molecules in gMG pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Few of the FcRn molecules in development include Rozanolixizumab (UCB Biopharma), SC efgartigimod (Argenx-Halozyme), Nipocalimab (Janssen), and Batoclimab (Immunovant Sciences).","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/08\/01155459\/generalized-myasthenia-gravis-treatment-market-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Generalized Myasthenia Gravis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">generalized myasthenia gravis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">generalized myasthenia gravis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">gmG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">gMG market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">gMG treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Generalized Myasthenia Gravis<\/span>","<span class=\"advgb-post-tax-term\">generalized myasthenia gravis market<\/span>","<span class=\"advgb-post-tax-term\">generalized myasthenia gravis treatment<\/span>","<span class=\"advgb-post-tax-term\">gmG<\/span>","<span class=\"advgb-post-tax-term\">gMG market<\/span>","<span class=\"advgb-post-tax-term\">gMG treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Aug 1, 2022","modified":"Updated on Nov 24, 2022"},"absolute_dates_time":{"created":"Posted on Aug 1, 2022 5:07 pm","modified":"Updated on Nov 24, 2022 6:35 pm"},"featured_img_caption":"generalized-myasthenia-gravis-treatment-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18256"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18257"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18256"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18256"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}